TY - JOUR
T1 - A roadmap towards personalized immunology
AU - Delhalle, Sylvie
AU - Bode, Sebastian F.N.
AU - Balling, Rudi
AU - Ollert, Markus
AU - He, Feng Q.
N1 - Funding Information:
This work was supported by the Luxembourg Personalized Medicine Consortium (PMC), Luxembourg National Research Fund (FNR) CORE program grant (CORE/14/ BM/8231540/GeDES, F.H.), FNR AFR-RIKEN bilateral program (TregBAR, F.H. and M.O.), PRIDE program grants (PRIDE/11012546/NEXTIMMUNE and PRIDE/10907093/CRITICS, for M.O., R.B. and F.H.) and European Academy of Allergy and Clinical Immunology (EAACI) long-term research fellowship (2016, S.B.).
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Big data generation and computational processing will enable medicine to evolve from a “one-size-fits-all” approach to precise patient stratification and treatment. Significant achievements using “Omics” data have been made especially in personalized oncology. However, immune cells relative to tumor cells show a much higher degree of complexity in heterogeneity, dynamics, memory-capability, plasticity and “social” interactions. There is still a long way ahead on translating our capability to identify potentially targetable personalized biomarkers into effective personalized therapy in immune-centralized diseases. Here, we discuss the recent advances and successful applications in “Omics” data utilization and network analysis on patients’ samples of clinical trials and studies, as well as the major challenges and strategies towards personalized stratification and treatment for infectious or non-communicable inflammatory diseases such as autoimmune diseases or allergies. We provide a roadmap and highlight experimental, clinical, computational analysis, data management, ethical and regulatory issues to accelerate the implementation of personalized immunology.
AB - Big data generation and computational processing will enable medicine to evolve from a “one-size-fits-all” approach to precise patient stratification and treatment. Significant achievements using “Omics” data have been made especially in personalized oncology. However, immune cells relative to tumor cells show a much higher degree of complexity in heterogeneity, dynamics, memory-capability, plasticity and “social” interactions. There is still a long way ahead on translating our capability to identify potentially targetable personalized biomarkers into effective personalized therapy in immune-centralized diseases. Here, we discuss the recent advances and successful applications in “Omics” data utilization and network analysis on patients’ samples of clinical trials and studies, as well as the major challenges and strategies towards personalized stratification and treatment for infectious or non-communicable inflammatory diseases such as autoimmune diseases or allergies. We provide a roadmap and highlight experimental, clinical, computational analysis, data management, ethical and regulatory issues to accelerate the implementation of personalized immunology.
UR - http://www.scopus.com/inward/record.url?scp=85047888329&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/29423275
U2 - 10.1038/s41540-017-0045-9
DO - 10.1038/s41540-017-0045-9
M3 - Review article
AN - SCOPUS:85047888329
SN - 2056-7189
VL - 4
JO - npj Systems Biology and Applications
JF - npj Systems Biology and Applications
IS - 1
M1 - 9
ER -